HC Wainwright Issues Positive Forecast for VYGR Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Analysts at HC Wainwright upped their Q1 2025 earnings estimates for Voyager Therapeutics in a report released on Thursday, March 13th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.21) per share for the quarter, up from their prior forecast of ($0.30). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.86) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($1.07) EPS, FY2028 earnings at ($1.47) EPS and FY2029 earnings at ($1.40) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $4.39 million during the quarter, compared to analysts’ expectations of $16.58 million. During the same quarter in the previous year, the company earned $1.25 EPS.

Several other research analysts have also weighed in on VYGR. Citigroup began coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price on the stock. Wedbush reissued an “outperform” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the company an “overweight” rating in a research report on Wednesday, March 12th. Canaccord Genuity Group decreased their target price on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $14.86.

Voyager Therapeutics Trading Down 0.3 %

NASDAQ VYGR opened at $3.89 on Monday. The company has a market capitalization of $212.50 million, a PE ratio of 5.48 and a beta of 0.99. Voyager Therapeutics has a 1-year low of $3.56 and a 1-year high of $10.66. The firm’s fifty day simple moving average is $4.79 and its 200-day simple moving average is $5.80.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Empowered Funds LLC boosted its position in shares of Voyager Therapeutics by 5.4% in the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after acquiring an additional 2,278 shares during the period. Rhumbline Advisers increased its position in Voyager Therapeutics by 3.4% during the fourth quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock worth $405,000 after acquiring an additional 2,354 shares during the period. Wells Fargo & Company MN raised its stake in Voyager Therapeutics by 3.7% during the 4th quarter. Wells Fargo & Company MN now owns 66,718 shares of the company’s stock valued at $378,000 after purchasing an additional 2,400 shares during the last quarter. Picton Mahoney Asset Management boosted its holdings in Voyager Therapeutics by 71.1% in the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after purchasing an additional 2,444 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after purchasing an additional 3,077 shares during the last quarter. 48.03% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, COO Robin Swartz sold 6,500 shares of the business’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 10,778 shares of company stock valued at $58,548. Company insiders own 4.53% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.